Precipio delivered record quarterly revenue of $7.3 million for the third quarter of 2026, significantly outperforming consensus estimates. The company achieved GAAP break-even status and generated $0.6 million in operating cash flow, supported by scaling proprietary product sales and stable pathology services.
Key Highlights
- Total revenue grew 8% year-over-year to $7.3 million, outperforming the conservative $1.68 million estimate.
- Product division revenue surged 40% year-over-year to $1.0 million, marking a significant milestone for the segment.
- The company achieved GAAP break-even net income of $0.0 million, an improvement from a $0.1 million loss in the prior year quarter.
- Adjusted EBITDA remained positive for the second consecutive quarter at $0.4 million, while the cash balance increased to over $3.5 million.